Nicole Defeudis is an Editor and Biopharma reporter for Endpoints News. Her articles cover a wide range of topics in the pharmaceutical industry, including mergers and acquisitions, regulatory approvals, drug pricing, and legal disputes. Nicole provides in-depth analysis and reporting on the latest developments in the biopharma sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Nicole's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly around regulatory approvals, legal policy regulation, and government announcements. She appears to be interested in stories related to FDA approvals, drug pricing, mergers and acquisitions within the pharmaceutical space.
To effectively reach out to Nicole with a pitch or as a source for her articles, it would be beneficial to provide insights or expertise related to recent developments in FDA regulations and approvals, legal challenges faced by pharmaceutical companies such as patent disputes or antitrust issues. Additionally, commentary on the implications of regulatory changes on drug pricing could also resonate well with her coverage focus.
It is important to note that Nicole tends to cover topics without geographic constraints explicitly mentioned. Therefore, pitches should focus on providing broader industry-specific insights rather than region-specific news unless otherwise indicated.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Nicole DeFeudis
California voters supported a state ballot measure on Tuesday that would increase oversight around the 340B federal drug discount program.
Pfizer is doubling down on its commitment to China as the company continues to face activist pressure around its plans for a …
By: Nicole DeFeudis
Amgen and AstraZeneca said on Friday that their asthma drug Tezspire reduced nasal congestion and the size of nasal polyps in patients with a different …
By: Max Gelman, Nicole DeFeudis
Welcome back to Endpoints Weekly, your review of the week's top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers …
Rapt Therapeutics is officially shelving its mid-stage immunology candidate after a case of liver failure triggered clinical holds earlier this year.
Syndax Pharmaceuticals said its experimental menin inhibitor met the primary endpoint in a pivotal trial for certain leukemia patients, and it's planning a regulatory filing …
Johnson & Johnson is suing the federal government over its rebuke of the company's alternative model for 340B drug price discounts.
By: Nicole DeFeudis
The European Medicines Agency has flipped its stance on Eisai and Biogen's Alzheimer's treatment Leqembi, recommending authorization in a narrower population than it previously considered …
By: Nicole Defeudis
Merz Therapeutics landed in hot water last month when the FDA said a social media promotion for its Botox rival Xeomin was “false or misleading.
By: Nicole DeFeudis
Eli Lilly is now the second drugmaker to propose a rebate model for 340B drug price discounts — and the second to sue over it. …
(833) 317-6278 
